Zealand Pharma A/S · OMXCOP:ZEAL
Zealand Pharma A/S — Q3 2019 Earnings Presentation
19 slides from Zealand Pharma A/S's earnings presentation, Nov 14, 2019
Slide 1: Interim report for the third quarter of 2019
Interim report for the third quarter of 2019 Zealand Pharma November 14, 2019
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains information pertaining to Zealand Pharma A/S (“Zealand"). Neither Zealand nor its management, directors, employees or representatives make any representation or warranty, express or implied, as to the accuracy or completeness of any of the inform
Slide 3: Business Highlights
Business Highlights Emmanuel Dulac President and Chief Executive Officer 2
Slide 4: A pivotal moment for Zealand Pharma
A pivotal moment for Zealand Pharma Fully integrated biotech company with medical and commercial operations Approaching commercialization Four potential product launches Establishing operations in the U.S. beginning in 2021 Dasiglucagon HypoPal® Accelerating late stage development Rescue Pen for s
Slide 5: Zealand Pharma has made impressive progress in 2019
Zealand Pharma has made impressive progress in 2019 Business • Endpoints achieved in pediatric Phase 3 study with dasiglucagon HypoPal® rescue pen highlights • Initiated Phase 2 clinical proof of concept trial with dasiglucagon in patients with serious in Q3 and meal-induced hypoglycemia following b
Slide 6: Orally-delivered a4b7 integrin inhibitor (ZP10000)
Orally-delivered a4b7 integrin inhibitor (ZP10000) added to early pipeline through Encycle Therapeutics acquisition α4β7 integrin inhibitor: ZP100001 Encycle Therapeutics acquisition • ZP10000 inhibits integrin α4β7, which is involved in • 100% contingent consideration with no upfront payment migrat
Slide 7: Preparing for commercialization in the U.S.
Preparing for commercialization in the U.S. Glepaglutide for short bowel syndrome Dasiglucagon Dasiglucagon Dasiglucagon ® HypoPal Rescue Pen for for congenital Dual Hormone severe hypoglycemia hyperinsulinism Artificial Pancreas 2020 2021 2022 2023 Potential product launches U.S. leadership, and
Slide 8: Financial Highlights
Financial Highlights Matt Dallas Chief Financial Officer 7
Slide 9: Maintaining financial strength to support our clinical programs
Maintaining financial strength to support our clinical programs Net Operating Expenses1 Strong cash position R&D and Administrative Expenses Cash and cash equivalents, restricted cash and marketable securities DKKm $m2 DKKm $m2 700 102 1.800 263 1.600 233 600 88 1.400 204 500 73 1.200 175 400 58 1.0
Slide 10: R&D Highlights
R&D Highlights Adam Steensberg Chief Medical & Development Officer 9
Slide 11: Three Phase 3 programs and a promising early pipeline
Three Phase 3 programs and a promising early pipeline Product Candidate Indication Pre-clinical Phase 1 Phase 2 Phase 3 Registration Glepaglutide GLP-2 Analog Short bowel syndrome ZP7570 GLP-1/GLP-2 Dual Agonist Short bowel syndrome Dasiglucagon HypoPal® Rescue Pen Severe hypoglycemia Dasiglucagon S
Slide 12: Advancing two promising programs for short bowel syndrome
Advancing two promising programs to address severe unmet medical needs for patients with short bowel syndrome Glepaglutide ZP 7570 GLP-2 Analog GLP-1R/GLP-2R dual agonist Pivotal Phase 3 Phase 1a • Evaluate once- and twice-weekly • Single-ascending dose glepaglutide dosing over 24 weeks • Safety and
Slide 13: Dasiglucagon HypoPal rescue pen on-track for early 2020 NDA submission
Dasiglucagon HypoPal® rescue pen for treatment of severe hypoglycemia on-track for early 2020 NDA submission Potential for fastest rescue from hypoglycemia For illustration only Pivotal Phase 31 Confirmatory Phase 33 Pediatric Phase 34 Median time to blood glucose recovery 40 min 35 min 30 min 10 mi
Slide 14: Multiple opportunities with dasiglucagon via different product modalities
We are pursuing multiple opportunities to improve patients’ lives with dasiglucagon via different product modalities Dasiglucagon Novel stable glucagon analog Fast onset-of-action Unique stability in liquid formulation Suitable for multiple indications HypoPal® rescue pen Dual hormone Infusion pump
Slide 15: Expanding treatment opportunities for dasiglucagon with a mini-dose concept
Expanding treatment opportunities for dasiglucagon with a mini-dose concept Post-bariatric surgery hypoglycemia (PBH) • Can lead to rapid gastric emptying, hyperinsulinemia and serious hypoglycemia 1-3 hours after food ingestion1 • Significant unmet need with currently no approved therapies Mini-dos
Slide 16: Boehringer Ingelheim partnership program: Next generation peptide therapeutics
Boehringer Ingelheim partnership program: Next generation peptide therapeutics for obesity / type 2 diabetes Long-term partnership to develop Study to test whether different doses of BI 456906 two product candidates are effective in treating adults with Type 2 Diabetes4 BI 456906 GLP-1/glucagon dual
Slide 17: Closing Remarks
Closing Remarks Emmanuel Dulac President and Chief Executive Officer 16
Slide 18: Zealand Pharma in 2019
Zealand Pharma in 2019 First dosing of patients in Patients enrolled in Phase 3 pivotal Phase 3 with extension with glepaglutide dasiglucagon (CHI) (SBS) Phase 1 completion with Collaboration Positive confirmatory Phase Strategic pipeline GLP-1/GLU dual agonist1 between Zealand 3 results
Slide 19: Q&A Upcoming investor presentations
Q&A Upcoming investor presentations Jefferies Healthcare Conference, London November 20 Nordea Innovation Seminar, Stockholm November 26 Økonomisk Ugebrev Investor Meeting, Copenhagen November 27 18